08:00 , Jan 7, 2002 |  BioCentury  |  Finance

Foresight in hindsight

Foresight in hindsight To mark the 10th Anniversary of the Buyside View, we have picked selected quotes from previous years - some prescient, others providing interesting historical perspective - and printed them below along with...
08:00 , Dec 9, 1996 |  BioCentury  |  Emerging Company Profile

Antigenics: Getting down to (patient) specifics

Antigenics: Getting down to (patient) specifics A challenge to developing cancer therapies is that any given cancer in any particular patient is genetically distinct. While a competent immune response may succeed in the elimination of...
08:00 , Jan 10, 1994 |  BioCentury  |  Finance

The buy-side view, redux

A year ago, in its premier issue, BioCentury asked fund managers what kinds of criteria they used to pick biotechnology stocks. One year, many clinical disasters, a few shining triumphs and a health care plan...
08:00 , Feb 1, 1993 |  BioCentury  |  Finance

Grass is greener syndrome

Grass is greener syndrome Two weeks ago, everyone was waiting with bated breath to see what shape this offerings window would take. Now that its outlines are becoming clear, we find the picture a bit...
08:00 , Jan 11, 1993 |  BioCentury  |  Finance

The buy-side view

Since December, at least 21 biotech companies have filed for public offerings, and everyone knows there are more coming. Just how fund managers wade through those competing demands for money will play an important role...